Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fortress Biotech, Inc. (FBIO)
Price$2.72Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.2M | $55.1M | $59.7M | $71.0M | $63.1M | $44.5M | $34.9M | $23.4M | $15.5M | $16.5M | $863,000 | $0 | $0 | — | — | — | — | — | — |
| Gross profit | $40.3M | $34.3M | $36.8M | $40.2M | $31.1M | $29.9M | $24.4M | $17.3M | $11.9M | $15.7M | $863,000 | — | — | — | — | — | — | — | — |
| Gross margin | 65.83% | 62.13% | 61.63% | 56.65% | 49.18% | 67.23% | 69.84% | 73.80% | 76.43% | 95.21% | 100.00% | — | — | — | — | — | — | — | — |
| Research & development | $11.9M | $56.6M | $101.7M | $134.2M | $113.2M | $61.3M | $6.1M | $83.3M | $48.3M | $35.1M | $29.8M | $10.2M | $25.7M | $17.5M | $8.6M | $8.3M | $2.3M | — | — |
| Operating expenses | $110.5M | $144.6M | $179.1M | $243.8M | $219.6M | $124.2M | $135.2M | $146.9M | $107.0M | $82.2M | $51.4M | $20.7M | $35.8M | — | — | — | — | — | — |
| Operating income | −$70.2M | −$110.4M | −$142.3M | −$203.6M | −$188.5M | −$94.3M | −$110.8M | −$120.0M | −$89.8M | −$65.7M | −$50.5M | −$20.7M | −$35.8M | −$27.2M | −$35.0M | −$9.2M | −$2.6M | — | — |
| Operating margin | −114.67% | −200.20% | −238.58% | −286.73% | −298.64% | −211.70% | −317.34% | −513.33% | −578.58% | −398.73% | −5,855.27% | — | — | — | — | — | — | — | — |
| EBITDA | −$65.6M | −$105.9M | −$136.3M | −$196.2M | −$185.9M | −$90.6M | −$107.7M | −$118.6M | −$88.6M | −$64.8M | −$50.5M | −$20.6M | −$35.8M | −$27.2M | −$35.0M | −$9.2M | −$2.6M | — | — |
| EBITDA margin | −107.06% | −192.10% | −228.53% | −276.33% | −294.47% | −203.39% | −308.48% | −507.38% | −571.08% | −393.00% | −5,852.26% | — | — | — | — | — | — | — | — |
| Net income | $6.8M | −$46.0M | −$60.6M | −$86.6M | −$64.7M | −$46.5M | −$40.0M | −$84.1M | −$66.9M | −$55.1M | −$48.4M | −$20.4M | −$37.2M | −$27.6M | −$36.4M | −$10.0M | −$3.7M | −$3.8M | −$2.6M |
| Net profit margin | 11.13% | −83.43% | −101.63% | −121.95% | −102.49% | −104.48% | −114.43% | −359.97% | −430.90% | −334.31% | −5,611.59% | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$11.84 | -$9.75 | -$10.94 | -$29.09 | -$24.14 | -$20.69 | -$18.59 | -$8.40 | -$18.29 | -$19.04 | -$82.61 | -$33.58 | -$15.14 | — | — |
| Diluted EPSper diluted share | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$11.84 | -$9.75 | -$10.94 | -$29.09 | -$24.14 | -$20.69 | -$18.59 | -$8.40 | -$18.29 | -$19.04 | -$82.61 | -$33.58 | -$15.14 | — | — |
Owners
Reported shareholders
≈13.77%of listed shares
ROSENWALD LINDSAY A MD4.59M shares · Mar 18, 2026
View holders
| Holder | % owned |
|---|---|
ROSENWALD LINDSAY A MD | ≈13.77%4.59M shares |
WEISS MICHAEL S | ≈6.83%2.28M shares |
Jin David | ≈4.96%1.65M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.11%1.04M shares |
Opaleye Management Inc. | 2.67%890K shares |
MACKENZIE FINANCIAL CORP | 1.67%555.68K shares |
GSA CAPITAL PARTNERS LLP | 1.38%458.47K shares |
SHIKIAR ASSET MANAGEMENT INC | 0.92%305.47K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.90%300.52K shares |
BlackRock, Inc. | 0.67%224.78K shares |
TWO SIGMA INVESTMENTS, LP | 0.64%213.79K shares |
LOBELL J JAY | ≈0.58%192.4K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.53%177.37K shares |
VANGUARD FIDUCIARY TRUST CO | 0.50%166.37K shares |
Harvey Jimmie | ≈0.44%146.7K shares |
Klein Dov | ≈0.39%130.11K shares |
HB Wealth Management, LLC | 0.35%116.68K shares |
Kestra Advisory Services, LLC | 0.35%116.24K shares |
Hoenlein Malcolm | ≈0.35%115.75K shares |
ACADIAN ASSET MANAGEMENT LLC | 0.32%107.3K shares |
Percentages use 33.31M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 23, 2024Form 4 | ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN | BuyCommon stock, par value $0.001 | 763.4K | $1.84 | $1.40M | 3.66M |
| Sep 23, 2024Form 4 | ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN | BuyWarrants to Purchase Common Stock · derivative | 763.4K | $0.13 | $99.2K | 763.4K |
| Jul 11, 2024Form 4 | ROSENWALD LINDSAY A MDPresident, CEO & Chairman | BuySERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5.0K | $7.48 | $37.4K | 127.5K |
| Jul 10, 2024Form 4 | Jin DavidChief Financial Officer | BuySERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 500 | $7.50 | $3.8K | 500 |
| Jul 9, 2024Form 4 | ROSENWALD LINDSAY A MDPresident, CEO & Chairman | BuySERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5.0K | $7.39 | $37.0K | 122.5K |